SUPPLEMENTARY FIGURES



Supplementary Figure 1. The relationship between CNV and expression of ferroptosis regulators.



Supplementary Figure 2. The relative location of 16 ferroptosis regulators.



Supplementary Figure 3. The PCA (A) and sample correlation heatmaps (B) of normal and tumor samples based on expression of ferroptosis regulators.



Supplementary Figure 4. Functional enrichment analysis of differentially expressed ferroptosis regulators between normal and tumor tissues. (A) Biological processes of upregulated ferroptosis regulators in tumor tissue. (B) Cell Component of up-regulated ferroptosis regulators in normal tissue.



Supplementary Figure 5. Expression of each ferroptosis regulators between STS cell and normal skeletal cell by RT-qPCR. (A–P) The relative expression of ACACA, ACSF2, AIFM2, CBS, CD44, CRYAB, FANCD2, GSS, HMGCR, HSPB1, NCOA4, NFE2L2, NQO1, RPL8, SLC1A5 and SQLE between tumor and normal cells, respectively. *p < 0.05, **p < 0.01, ***p = 0.



Supplementary Figure 6. Immune infiltration of each sample in TCGA-SARC.



Supplementary Figure 7. Functional enrichment analysis of DEGs between two ferroptosis modification patterns.



Supplementary Figure 8. Validation of Fescore in different subtypes of STS. (A) The survival plot between high and low Fescore group in UDS. (B, C) The survival plot and grading differences between high and low Fescore groups in LMS. (D, E) The metastasis and CINSARC index between high and low Fescore groups in SS. (F) The survival plot between high and low Fescore group in ES. (G, H) The metastasis and CINSARC index between high and low Fescore groups in FS. (I, J) The metastasis and Grading between high and low Fescore groups in FS.



Supplementary Figure 9. Protein-protein interaction analysis of genes that constructed Fescore.